In Brief: Roche Zenapax
Executive Summary
Roche Zenapax: Not effective for reducing the incidence of Graft-v.-Host Disease following bone marrow transplantation in Phase II/III study, Roche and development partner Protein Design Labs report June 30. Roche is continuing Phase III trials of monoclonal antibody Zenapax (humanized Anti-Tac) for prevention of acute rejection in kidney transplantation...